Literature DB >> 12693428

Review of antipsychotic medication administration: a proposal of intermittent dosing.

Roger A Boshes1, Theo C Manschreck.   

Abstract

Despite advances in the treatment of schizophrenia, there are substantial gaps in systematically established knowledge concerning the application of antipsychotic agents. We still do not know how antipsychotic drugs work, where they work, how much to prescribe, or how often to prescribe. No consensus exists on the definition of relapse or recovery. Based on new knowledge of delayed onset and offset of pharmacological response in schizophrenia, of signal transduction, of time-delayed effects at the neuronal level, and of the complexities of etiologic and clinical heterogeneity in these disorders, we propose an alternative dosing strategy. Fixed intermittent dosing for initiation and maintenance of remission of clinical symptoms holds promise for improving response to medication, reducing side effects, increasing compliance, and limiting cost. It may help clarify the taxonomic conundrum of schizophrenia by providing a probe for identifying discrete pathophysiologic substrates in these disorders.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12693428     DOI: 10.1093/oxfordjournals.schbul.a006932

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  3 in total

Review 1.  Antipsychotic dosing: how much but also how often?

Authors:  Gary Remington; Shitij Kapur
Journal:  Schizophr Bull       Date:  2010-07-21       Impact factor: 9.306

2.  Predictive validity of proposed remission criteria in first-episode schizophrenic patients responding to antipsychotics.

Authors:  Lex Wunderink; Fokko J Nienhuis; Sjoerd Sytema; Durk Wiersma
Journal:  Schizophr Bull       Date:  2006-08-07       Impact factor: 9.306

Review 3.  Effect of second-generation antipsychotics on employment and productivity in individuals with schizophrenia: an economic perspective.

Authors:  Mauro Percudani; Corrado Barbui; Michele Tansella
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.